http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102145665-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2018-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102145665-B1 |
| titleOfInvention | Nucleic acids for simultaneous inhibition of BCL2 gene and BI-1 gene |
| abstract | The present invention relates to a nucleic acid molecule that simultaneously suppresses the expression of the BCL2 gene and the BI-1 gene, and to a pharmaceutical composition for anticancer comprising the same, and specifically, to overcome the disadvantage of not having a high therapeutic effect due to the target specificity of siRNA. For this purpose, the double-stranded siRNA of the present invention, designed to simultaneously inhibit the expression of the BCL2 gene and BI-1 gene related to cancer, promotes the death of cancer cells, and has the effect of synergistically improving cancer cell death in combination treatment with an anticancer agent. , It can be usefully used as an anticancer composition or anticancer adjuvant for various cancer types. |
| priorityDate | 2018-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 364.